Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Compare

1,459 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IONS Analyst Ratings

Strong Buy

15 Buy

3 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$87.69

▲(11.89% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $87.69 with a high forecast of $110.00 and a low forecast of $65.00. The average price target represents a 11.89% change from the last price of $78.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","111":"$111","47.25":"$47.3","68.5":"$68.5","89.75":"$89.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$87.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,47.25,68.5,89.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,84.14461538461538,86.29923076923076,88.45384615384614,90.60846153846154,92.76307692307692,94.9176923076923,97.07230769230769,99.22692307692307,101.38153846153847,103.53615384615384,105.69076923076923,107.84538461538462,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,82.42846153846153,82.86692307692307,83.30538461538461,83.74384615384615,84.18230769230769,84.62076923076923,85.05923076923077,85.4976923076923,85.93615384615384,86.37461538461538,86.81307692307692,87.25153846153846,{"y":87.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,80.68307692307692,79.37615384615384,78.06923076923077,76.76230769230769,75.45538461538462,74.14846153846153,72.84153846153846,71.53461538461538,70.22769230769231,68.92076923076922,67.61384615384615,66.30692307692307,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$87.69

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Abrahams

RBC Capital

$82→$95

Buy

21.22%

Upside

Reiterated

12/17/25

RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Mani Foroohar

Leerink Partners

$85→$100

Buy

27.60%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Jason Gerberry

Bank of America Securities

$86→$97

Buy

23.77%

Upside

Reiterated

12/08/25

Bank of America Securities Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Jim Birchenough

Wells Fargo

$100→$82

Buy

4.63%

Upside

Reiterated

12/08/25

Wells Fargo Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Yaron Werber

TD Cowen

$99

Buy

26.32%

Upside

Reiterated

12/03/25

Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships

Mitchell Kapoor

H.C. Wainwright

$110

Buy

40.36%

Upside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), Akebia Therapeutics (NASDAQ: AKBA) and Ionis Pharmaceuticals (NASDAQ: IONS)

Myles Minter

William Blair

Buy

―

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and IDEAYA Biosciences (NASDAQ: IDYA)

William Pickering

Bernstein

$65

Hold

-17.06%

Downside

Reiterated

11/18/25

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

Joseph Stringer

Needham

$90

Buy

14.84%

Upside

Reiterated

11/10/25

Analysts Are Bullish on These Healthcare Stocks: Xtant Medical Holdings (XTNT), Ionis Pharmaceuticals (IONS)

Michael Ulz

Morgan Stanley

$94

Buy

19.94%

Upside

Reiterated

11/10/25

Ionis Pharmaceuticals' Olezarsen: Promising Phase 3 Results and Blockbuster Potential Justify Buy Rating

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

11/09/25

Promising Potential of Ionis Pharmaceuticals' Olezarsen Drives Buy Rating

Allison Bratzel

Piper Sandler

$70→$77

Buy

-1.75%

Downside

Reiterated

11/04/25

Ionis Pharmaceuticals price target raised to $77 from $70 at Piper SandlerIonis Pharmaceuticals price target raised to $77 from $70 at Piper Sandler

Gena Wang

Barclays

$80→$95

Buy

21.22%

Upside

Reiterated

10/30/25

Ionis Pharmaceuticals (IONS) Receives a Buy from Barclays

Jay Olson

Oppenheimer

$90

Buy

14.84%

Upside

Reiterated

10/27/25

Oppenheimer Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Raymond James

$75→$85

Buy

8.46%

Upside

Reiterated

10/09/25

Raymond James Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Abrahams

RBC Capital

$82→$95

Buy

21.22%

Upside

Reiterated

12/17/25

RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Mani Foroohar

Leerink Partners

$85→$100

Buy

27.60%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Jason Gerberry

Bank of America Securities

$86→$97

Buy

23.77%

Upside

Reiterated

12/08/25

Bank of America Securities Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Jim Birchenough

Wells Fargo

$100→$82

Buy

4.63%

Upside

Reiterated

12/08/25

Wells Fargo Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Yaron Werber

TD Cowen

$99

Buy

26.32%

Upside

Reiterated

12/03/25

Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships

Mitchell Kapoor

H.C. Wainwright

$110

Buy

40.36%

Upside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), Akebia Therapeutics (NASDAQ: AKBA) and Ionis Pharmaceuticals (NASDAQ: IONS)

Myles Minter

William Blair

Buy

―

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and IDEAYA Biosciences (NASDAQ: IDYA)

William Pickering

Bernstein

$65

Hold

-17.06%

Downside

Reiterated

11/18/25

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

Joseph Stringer

Needham

$90

Buy

14.84%

Upside

Reiterated

11/10/25

Analysts Are Bullish on These Healthcare Stocks: Xtant Medical Holdings (XTNT), Ionis Pharmaceuticals (IONS)

Michael Ulz

Morgan Stanley

$94

Buy

19.94%

Upside

Reiterated

11/10/25

Ionis Pharmaceuticals' Olezarsen: Promising Phase 3 Results and Blockbuster Potential Justify Buy Rating

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

11/09/25

Promising Potential of Ionis Pharmaceuticals' Olezarsen Drives Buy Rating

Allison Bratzel

Piper Sandler

$70→$77

Buy

-1.75%

Downside

Reiterated

11/04/25

Ionis Pharmaceuticals price target raised to $77 from $70 at Piper SandlerIonis Pharmaceuticals price target raised to $77 from $70 at Piper Sandler

Gena Wang

Barclays

$80→$95

Buy

21.22%

Upside

Reiterated

10/30/25

Ionis Pharmaceuticals (IONS) Receives a Buy from Barclays

Jay Olson

Oppenheimer

$90

Buy

14.84%

Upside

Reiterated

10/27/25

Oppenheimer Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Raymond James

$75→$85

Buy

8.46%

Upside

Reiterated

10/09/25

Raymond James Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

1 Month

xxx

Success Rate

15/22 ratings generated profit

Average Return

+4.67%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.18% of your transactions generating a profit, with an average return of +4.67% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+12.63%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +12.63% per trade.

1 Year

Gary NachmanRaymond James

Success Rate

18/22 ratings generated profit

Average Return

+38.21%

reiterated a buy rating 2 months ago

Copying Gary Nachman's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +38.21% per trade.

2 Years

xxx

Success Rate

33/34 ratings generated profit

Average Return

+46.81%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +46.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IONS has received 34 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 87.69.

Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.31 with a range of -$1.51 to -$0.95. The previous quarter’s EPS was -$0.80. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $153.95M with a range of $125.00M to $180.46M. The previous quarter’s sales results were $156.72M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 87.69.

What is IONS’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 11.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IONS a Buy, Sell or Hold?

Ionis Pharmaceuticals has a consensus rating of Strong Buy which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals’s price target?

The average price target for Ionis Pharmaceuticals is 87.69. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $65.00. The average price target represents 11.89% Increase from the current price of $78.37.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of IONS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

IONS Analyst Ratings

IONS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

IONS Analyst Recommendation Trends

IONS Financial Forecast

IONS Earnings Forecast

IONS Sales Forecast

IONS Stock Forecast FAQ

Detailed List of Analyst Forecasts